Treatment outcomes and resource use of patients with neurogenic detrusor overactivity receiving botulinum toxin A (BOTOX®) therapy in Germany

World Journal of Urology

Volumn 28, Issue 3, 2010, Pages 385-390

  Wefer, Björn ^a   Ehlken, Birgit ^b   Bremer, Jörn ^c   Burgdörfer, Harald ^d   Domurath, Burkhard ^e   Hampel, Christian ^f   Kutzenberger, Johannes ^e   Seif, Christoph ^a   Sievert, Karl D ^g   Berger, Karin ^b   Pannek, Jürgen ^h,i  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b IQVIA   (United States)

^c Neurologisches Rehabilitationszentrum Greifswald GmbH   (Germany)

^d BG Unfallkrankenhaus Hamburg   (Germany)

^e Werner Wicker Klinik   (Germany)

^f UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^g UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^h RUHR UNIVERSITY BOCHUM   (Germany)

ⁱ SWISS PARAPLEGIC RESEARCH   (Switzerland)

Author keywords

Bladder; Botulinum toxin A; Neurogenic detrusor overactivity; Spinal cord injury; Urinary incontinence

Indexed keywords

BOTULINUM TOXIN A;

ADULT; ARTICLE; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; COHORT ANALYSIS; COST BENEFIT ANALYSIS; COST OF ILLNESS; CROSS-SECTIONAL STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; ECONOMICS; FEMALE; FOLLOW UP; GERMANY; HOSPITALIZATION; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; MENINGOMYELOCELE; MIDDLE AGED; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NEUROGENIC BLADDER; NONPARAMETRIC TEST; OVERACTIVE BLADDER; PROBABILITY; QUALITY OF LIFE; RETROSPECTIVE STUDY; SPINAL CORD INJURY; TREATMENT OUTCOME; URODYNAMICS;

ADULT; BOTULINUM TOXIN TYPE A; CHI-SQUARE DISTRIBUTION; COHORT STUDIES; COST OF ILLNESS; COST-BENEFIT ANALYSIS; CROSS-SECTIONAL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GERMANY; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MENINGOMYELOCELE; MIDDLE AGED; MULTIPLE SCLEROSIS; PROBABILITY; QUALITY OF LIFE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SPINAL CORD INJURIES; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; URINARY BLADDER, NEUROGENIC; URINARY BLADDER, OVERACTIVE; URODYNAMICS; YOUNG ADULT;

EID: 77952879131     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-009-0466-1     Document Type: Article

References (21)

1. Webb DR, Fitzpatrick JM, O′Flynn JD (1984) A 15-year follow-up of 406 consecutive spinal cord injuries. Br J Urol 56: 614-617.
2. Gerridzen RG, Thijssen AM, Dehoux E (1992) Risk factors for upper tract deterioration in chronic spinal cord injured patients. J Urol 147: 416-418.
3. Bruschini H, Almeida FG, Srougi M (2006) Upper and lower urinary tract evaluation of 104 patients with myelomeningocele without adequate urological management. World J Urol 24: 224-228.
4. DasGupta R, Fowler CJ (2003) Bladder, bowel and sexual dysfunction in multiple sclerosis: management strategies. Drugs 63: 153-166.
5. Horstmann M, Schaefer T, Aguilar Y, Stenzl A, Sievert KD (2006) Neurogenic bladder treatment by doubling the recommended antimuscarinic dosage. Neurourol Urodyn 25: 441-445.
6. Groah SL, Weitzenkamp DA, Lammertse DP, Whiteneck GG, Lezotte DC, Hamman RF (2002) Excess risk of bladder cancer in spinal cord injury: evidence for an association between indwelling catheter use and bladder cancer. Arch Phys Med Rehabil 83: 346-351.
7. Schurch B, Stöhrer M, Kramer G, Schmid DM, Gaul G, Hauri D (2000) Botulinum-a toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 164: 692-697.
8. Schurch B, de Seze M, Denys P, Chartier-Kastler E, Haab F, Everaet K, Plante P, Perrouin-Verbe B, Kumar C, Fraczek S, Brin MF, Botox Detrusor Hyperreflexia Study Team (2005) Botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 174: 196-200.
9. Apostolidis A, Dasgupta P, Denys P, Elneil S, Fowler CJ, Giannantoni A, Karsenty G, Schulte-Baukloh H, Schurch B, Wyndaele JJ (2008) Recommendations on the use of Botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report. Eur Urol [Epub ahead of print].
10. Kuo HC (2006) Therapeutic effects of suburothelial injection of botulinum a toxin for neurogenic detrusor overactivity due to chronic cerebrovascular accident and spinal cord lesions. Urology 67: 232-236.
11. Kalsi V, Popat RB, Apostolidis A, Kavia R, Odeyemi IA, Dakin HA, Warner J, Elneil S, Fowler CJ, Dasgupta P (2006) Cost-consequence analysis evaluating the use of Botulinum neurotoxin-a in patients with detrusor overactivity based on clinical outcomes observed at a single UK centre. Eur Urol 49: 519-527.
12. Stöhrer M, Blok B, Castro-Diaz D, Chartier-Kastler E, Del Popolo G, Kramer G, Pannek J, Radziszewski P, Wyndaele JJ (2009) EAU guidelines on neurogenic lower urinary tract dysfunction. Eur Urol [Epub ahead of print].
13. Rote Liste (2006) Rote Liste Service GmbH. Frankfurt/Main, Germany.
14. Reitz A, Stöhrer M, Kramer G, Del Popolo G, Chartier-Kastler E, Pannek J, Burgdörfer H, Göcking K, Madersbacher H, Schumacher S, Richter R, von Tobel J, Schurch B (2004) European experience of 200 cases treated with botulinum-a toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 45: 510-515.
15. Sievert KD, Bremer J, Burgdörfer H, Domurath B, Hampel C, Kutzenberger J, Seif C, Stöhrer M, Wefer B, Pannek J (2007) Botulinumtoxin in der Therapie der neurogenen Detrusorhyperaktivität. Konsensuspapier zum Einsatz bei einer neurogenen Blasenfunktionsstörung. Urologe A 46: 293-296.
16. Giannantoni A, Di Stasi SM, Stephen RL, Bini V, Costantini E, Porena M (2004) Intravesical resiniferatoxin versus botulinum-a toxin injections for neurogenic detrusor overactivity: a prospective randomized study. J Urol 172: 240-243.
17. Popat R, Apostolidis A, Kalsi V, Gonzales G, Fowler CJ, Dasgupta P (2005) A comparison between the response of patients with idiopathic detrusor overactivity and nerogenic detrusor overactivity to the first intradetrusor injection of botulinum-a toxin. J Urol 174: 984-989.
18. Schulte-Baukloh H, Weiss C, Stolze T, Herholz J, Stürzebecher B, Miller K, Knispel HH (2005) Botulinum-a toxin detrusor and sphincter injection in treatment of overactive bladder syndrome: objective outcome and patient satisfaction. Eur Urol 48: 984-990.
19. Hinkel A, Finke W, Bötel U, Gatermann SG, Pannek J (2004) Increasing resistance against antibiotics in bacteria isolated from the lower urinary tract of an outpatient population of spinal cord injury patients. Urol Int 73: 143-148.
20. Gamè X, Castel-Lacanal E, Bentaleb Y, Thiry-Escudiè I, De Boissezon X, Malavaud B, Marque P, Rischmann P (2008) Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections. Eur Urol 53: 613-618.
21. Wu JM, Siddiqui NY, Amundsen CL, Myers ER, Havrilesky LJ, Visco AG (2009) Cost-effectiveness of botulinum toxin A versus anticholinergic medications for idiopathic urge incontinence. J Urol 181: 2181-2186.